The company’s lead candidate, GLSI-100, relies on this specific batch of GP2 to prevent breast cancer from returning. While the stock currently trades at $19.66, it remains down 3.2% for the year. This European authorization allows clinical sites to align their protocols with the U.S. supply chain, which has utilized the same lot since early 2026.
In section Market Quotes
Greenwich LifeSciences Stock Climbs on European GP2 Approval
A 4.2% jump in Greenwich LifeSciences shares followed the European Medicines Agency's clearance of the company’s GP2 active ingredient for use in breast cancer immunotherapy trials. The development marks a significant logistical milestone as the firm expands its reach beyond the United States to combat cancer recurrence.
Operations are scaling rapidly, with the total number of participating clinical sites across both regions now reaching between 170 and 180. Shipments of the ingredient are currently moving toward European pharmacies. Simultaneously, Greenwich LifeSciences is navigating independent regulatory pathways in the United Kingdom and Canada to secure further approval for the same manufacturing lot.
Comments (0)
No comments yet. Be the first!